• Sunstone Life Science Ventures flagged a structural funding squeeze in Europe’s biotech market, with early-stage startups and near-commercial firms losing access to capital.
• It cited a fundraising shortfall despite steady deployment, warning VC dry powder fell 19% from a $743.9 billion 2023 peak to $600.9 billion.
• Pre-seed and seed were the weakest segment, with global biopharma seed and Series A rounds dropping to 191 in 2025 from 228 in 2024.
• At the late stage, it pointed to a public-market “sovereignty” gap, noting 66 of 67 EU biotech IPOs listed outside Europe.
• It called for more specialist early-stage vehicles, plus a consolidated European biotech-capable public market to reduce reliance on Nasdaq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunstone Life Science Ventures A/S published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.